These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35117336)

  • 1. Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review.
    Shen H; Wu C; Chen L; Zhang R
    Transl Cancer Res; 2020 Nov; 9(11):7366-7371. PubMed ID: 35117336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin-like anticoagulant associated with multiple myeloma and neutralized with protamine sulfate.
    Torjemane L; Guermazi S; Ladeb S; Ben Romdhane N; Lakhal A; Abdelkefi A; Ben Othman T; Ben Abdelhadhim A
    Blood Coagul Fibrinolysis; 2007 Apr; 18(3):279-81. PubMed ID: 17413766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-like anticoagulant associated with plasma cell myeloma.
    Chapman GS; George CB; Danley DL
    Am J Clin Pathol; 1985 Jun; 83(6):764-6. PubMed ID: 3923825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AGA Clinical Practice Update: Coagulation in Cirrhosis.
    O'Leary JG; Greenberg CS; Patton HM; Caldwell SH
    Gastroenterology; 2019 Jul; 157(1):34-43.e1. PubMed ID: 30986390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.
    Dager WE; White RH
    Ann Pharmacother; 2003 Sep; 37(9):1232-6. PubMed ID: 12921505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A heparin-like anticoagulant in a patient with Wegener's granulomatosis].
    Chrobák L; Rozsíval V; Herout V
    Bratisl Lek Listy; 1990 May; 91(5):396-8. PubMed ID: 2383776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulant effects of protamine sulfate in a canine model.
    Kresowik TF; Wakefield TW; Fessler RD; Stanley JC
    J Surg Res; 1988 Jul; 45(1):8-14. PubMed ID: 3392995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation.
    Ni Ainle F; Preston RJ; Jenkins PV; Nel HJ; Johnson JA; Smith OP; White B; Fallon PG; O'Donnell JS
    Blood; 2009 Aug; 114(8):1658-65. PubMed ID: 19531655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating heparin-like anticoagulants: Case report and review of literature.
    Hou C; Moffat KA; Gangji AS; Ning S
    Transfusion; 2021 Mar; 61(3):968-973. PubMed ID: 33350473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor.
    Shinagawa A; Kojima H; Berndt MC; Kaneko S; Suzukawa K; Hasegawa Y; Shigeta O; Nagasawa T
    Thromb Haemost; 2005 May; 93(5):889-96. PubMed ID: 15886805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of life-threatening bleeding with protamine sulfate in a patient with plasma cell leukemia.
    VanDommelen K; Omer Z; Hambley BC; Stefaniuk CM
    Blood Coagul Fibrinolysis; 2022 Oct; 33(7):425-428. PubMed ID: 35946464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulation protein function VI: augmentation of anticoagulant function by acetaldehyde-treated heparin.
    Brecher AS; Hellman K; Basista MH
    Dig Dis Sci; 1999 Jul; 44(7):1349-55. PubMed ID: 10489917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney failure as an unusual initial presentation of biclonal gammopathy (IgD multiple myeloma associated with light chain disease)--a case report.
    Rabrenović V; Mijušković Z; Marjanović S; Rabrenović M; Jovanović D; Antić S; Ignjatović L; Petrović M; Pilcević D
    Vojnosanit Pregl; 2015 Feb; 72(2):196-9. PubMed ID: 25831916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report of three cases of circulating heparin-like anticoagulants.
    Llamas P; Outeiriño J; Espinoza J; Santos AB; Román A; Tomás JF
    Am J Hematol; 2001 Aug; 67(4):256-8. PubMed ID: 11443639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of a heparin-like anticoagulant from the plasma of a patient with metastatic bladder carcinoma.
    Tefferi A; Owen BA; Nichols WL; Witzig TE; Owen WG
    Blood; 1989 Jul; 74(1):252-4. PubMed ID: 2752113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation.
    Ambühl PM; Wüthrich RP; Korte W; Schmid L; Krapf R
    Nephrol Dial Transplant; 1997 Nov; 12(11):2355-64. PubMed ID: 9394323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of activated human protein C on disseminated intravascular coagulation induced by lipopolysaccharide in rats.
    Aoki Y; Ota M; Katsuura Y; Komoriya K; Nakagaki T
    Arzneimittelforschung; 2000 Sep; 50(9):809-15. PubMed ID: 11050697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coagulation Testing in the Core Laboratory.
    Winter WE; Flax SD; Harris NS
    Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
    Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.